Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

Rhea-AI Summary

Disc Medicine, a clinical-stage biopharmaceutical company (NASDAQ:IRON), announced a virtual KOL investor event scheduled for April 25, 2023, to discuss erythropoietic protoporphyria (EPP). This rare and severe disease is caused by mutations in the heme biosynthesis pathway. The event will feature presentations from experts who will address the disease's epidemiology, pathophysiology, and unmet patient needs. Leadership will also outline development plans for bitopertin, an investigational therapy aimed at treating EPP. Currently, there is no cure for EPP, and only one FDA-approved treatment exists. The event will be webcast live, with a replay available for 90 days. For further details, visit Disc's investor webpage.

WATERTOWN, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today it will host a virtual KOL investor event on Tuesday, April 25, 2023, at 1:00 pm ET/ 10:00 am PT to provide an overview of erythropoietic protoporphyria (EPP), a rare, severe disease caused by mutations in the heme biosynthesis pathway. The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.

Intended for investors and other interested audiences, the virtual event will feature presentations from leading porphyria experts, who will provide a disease overview and discuss epidemiology, pathophysiology, disease burden, and unmet need associated with EPP. Invited speakers will include:

• Bruce Wang, M.D., Professor of Gastroenterology, University of California San Francisco, who runs the USCF Porphyria Center and is a principal investigator in the US Porphyrias Consortium. In addition to porphyria research, he also runs a research laboratory studying liver biology.
• Jean-Charles Deybach, M.D., Ph.D., Professor of Medicine, Paris Diderot University, who has been a porphyria specialist for more than 40 years, including running the French reference center for porphyria and acting as president of the European Porphyria Network (EPNET).

Members of Disc’s leadership will also review the therapeutic rationale for bitopertin in EPP and the trial designs of its ongoing phase 2 studies in BEACON and AURORA. The company will also review expectations and timing for data readouts in 2023.

A live webcast of the event will be available in the Events and Presentations section of the Investor page of Disc’s website (https://ir.discmedicine.com/). A webcast replay will be available after the live presentation and will be accessible for 90 days. Please register for the event on the Events and Presentations page of Disc’s website or by clicking this link.

About EPP

EPP is a rare, debilitating and potentially life-threatening disease caused by mutations that affect heme biosynthesis, resulting in the accumulation of a toxic, photoactive intermediate, PPIX. This causes severe reactions when patients are exposed to sunlight, characterized by excruciating pain, edema, burning sensations and potential blistering and disfigurement. PPIX also accumulates in the hepatobiliary system and can result in complications including gallstones, cholestasis, and liver damage in 20-30% of patients and in extreme cases liver failure. Current standard of care involves extreme measures to avoid sunlight, including restricting outdoor activities to nighttime, use of protective clothing and opaque shields, and pain management. This has a significant impact on the psychosocial development, quality of life, and daily activities of patients, particularly in young children and families. There is currently no cure for EPP and only one FDA-approved therapy, a surgically implanted synthetic hormone designed to stimulate melanin production called Scenesse® (afamelanotide).

About Bitopertin

Bitopertin is an investigational, clinical-stage, orally-administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is planning to develop bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. There are currently two ongoing Phase 2 clinical studies of bitopertin in patients with erythropoietic porphyria, including an open-label trial called BEACON and a randomized, double-blind placebo-controlled trial called AURORA.

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.

About Disc

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Disc Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectations with respect to its AURORA Phase 2 and BEACON Phase 2 clinical studies of bitopertin and projected timelines for the initiation and completion of its clinical trials and other activities. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2022 and other documents filed by Disc from time to time with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Disc’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com

Investor Relations Contact

Suzanne Messere
Stern Investor Relations
suzanne.messere@sternir.com

FAQ

What is the purpose of the Disc Medicine investor event on April 25, 2023?

The event aims to discuss erythropoietic protoporphyria (EPP) and the development plans for bitopertin.

Who are the featured speakers at the Disc Medicine event?

Speakers include Bruce Wang, M.D., and Jean-Charles Deybach, M.D., both experts in porphyria.

What is erythropoietic protoporphyria (EPP)?

EPP is a rare and debilitating disease caused by mutations affecting heme biosynthesis, leading to severe reactions to sunlight.

What is bitopertin and its significance in EPP treatment?

Bitopertin is an investigational oral therapy designed to modulate heme biosynthesis, potentially serving as a first disease-modifying treatment for EPP.

How can I access the webcast of the Disc Medicine investor event?

The webcast will be available on Disc's Investor page and can be accessed live or as a replay for 90 days.